Project 2
项目2
基本信息
- 批准号:10707440
- 负责人:
- 金额:$ 21.02万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-09-20 至 2027-06-30
- 项目状态:未结题
- 来源:
- 关键词:AddressAdoptive TransferAgeAirAir PollutionApicalAreaAsthmaAtlasesAtmosphereBiomedical ResearchCell LineCell modelCellsChemicalsChildChild HealthChildhoodCoculture TechniquesCollaborationsCommunitiesDataData SetDevelopmentDisastersElementsEmergency SituationEnvironmentEpithelial CellsEpitheliumEvaluationEventExhibitsExposure toFire - disastersGeneticHazard IdentificationHazardous SubstancesHealthHomeostasisHumanHurricaneIn VitroIndividualInflammationInhalation ExposureInjuryLaboratoriesLifeLiquid substanceLocationLungMeasurementMediatingMethodsModelingMolecularMonitorMorphologyNeighborhoodsOutcomeOutcome StudyPathogenesisPathologicPatternPermeabilityPhenotypePhysiciansPopulationPredispositionPreventionProcessProteinsProteomeProteomicsProtonsRaceReactionResearchResearch Project GrantsResourcesRespiration DisordersRiskRisk AssessmentRoleSamplingScienceScientistSignal TransductionSuperfundSurfaceTestingTexasToxicity TestsTranslatingTranslational ResearchUniversitiesWorkair monitoringair samplingairway epitheliumbronchial epitheliumcell typedesigndetection methodexosomeexperimental studyextracellular vesiclesgas analyzerhazardhigh riskimprovedin vitro Modelin vivoindividual variationirritationlung injurymass spectrometermobile computingnovelpopulation basedpotential biomarkerpreservationprogramsprotein expressionrespiratoryrespiratory healthresponseresponse to injurysexsuperfund sitethree-dimensional modelingtime usetooltraining opportunityvolatile organic compound
项目摘要
Project 2 ABSTRACT
Project 2 is a new Biomedical Research Project aimed at developing novel tools to rapidly characterize pediatric
respiratory health risks from exposure to hazardous volatile organic compounds (VOCs). This work will be a
critical element in the overall strategy of the Texas A&M University Superfund Research Center to characterize
and manage the human health risks associated with exposure to environmental emergency-mobilized hazardous
substances. Current toxicity testing strategies do not account for developmental stage that is representative of
the pediatric lung or encompass human population variability, even though these factors (i.e., age, sex, race,
and genetics) are critical in asthma risk. Moreover, mechanisms of action underlying individual/combined VOCs
on asthma pathogenesis is poorly understood. To support the evaluation of hazardous VOCs, including real
urban mixtures, and elucidate mechanistic linkages, Project 2 will test the hypothesis that the pediatric airway is
distinctly susceptible to pulmonary injury from hazardous VOCs, and that airway responses are modulated by
extracellular vesicle (EV)-mediated signaling. The research team brings together a toxicologist, a physician-
scientist and an atmospheric chemist to address the following specific aims. Aim 1 prioritizes the evaluation of
20 individual Superfund-priority VOCs to test for asthma-related phenotypes in vitro, first using a respiratory
epithelial cell line (16HBE) cultured at air-liquid interface, and then in a population-based, age-appropriate model
comprised of pediatric bronchial epithelial cells from the Developing Lung Molecular Atlas Program. Next,
representative designed mixtures matching environmentally-relevant proportions of chemicals in ambient air will
be evaluated in the standard and population-based pediatric cell lines. These responses will inform aim 2
mechanistic studies, which will test the hypothesis that VOC exposures alter EV protein expression, underlying
respiratory dysfunction. It is known that inflammation and epithelial barrier function are mediated by exosomes,
a class of secreted EVs ranging from 30 to 150 nm. In aim 2, EVs derived from 16HBE cells exposed to select
VOCs/mixtures will be purified and sequenced using a high-throughput proteomics approach. Protein signatures
revealed in this model will then be validated across diverse pediatric donor cell lines. Last, the functional role of
VOC-exposed, cell-derived EVs will be evaluated using adoptive transfer experiments. In parallel to aims 1 and
2, aim 3 objectives will characterize VOC mixtures through mobile air monitoring across different locations in the
greater Houston Area during baseline and in response to environmental disasters. Additionally, to fill in gaps in
disaster-related toxicity testing, 16HBE cells will be directly exposed to ambient air onboard the mobile platform
in the field, using time-resolved measurements to drive conditional sampling of different air masses. Outcomes
from the studies proposed in Project 2 are highly relevant to the Superfund Program. Overall, the novel tools and
findings will improve basic understanding of mechanisms underlying VOC-induced pediatric pulmonary injury
and enable improved risk assessment to rapidly characterize respiratory hazards that threaten children’s health.
项目2
项目2是一个新的生物医学研究项目,旨在开发新的工具,以快速表征儿科
暴露于有害挥发性有机化合物(VOC)的呼吸系统健康风险。这项工作将是
德克萨斯A&M大学超级基金研究中心整体战略的关键要素,
管理与接触环境紧急情况相关的人类健康风险
物质.目前的毒性测试策略没有考虑发育阶段,这是代表
小儿肺或包括人类群体变异性,即使这些因素(即,年龄性别种族
和遗传学)在哮喘风险中至关重要。此外,单个/组合VOC的作用机制
对哮喘的发病机制了解甚少。支持有害VOC的评估,包括真实的
城市混合物,并阐明机械联系,项目2将测试假设,即小儿气道是
明显易受有害VOC的肺损伤,气道反应受
细胞外囊泡(EV)介导的信号传导。研究小组召集了一位毒理学家,一位医生-
科学家和大气化学家致力于实现以下具体目标。目标1优先评价
20个超级基金优先的VOC体外测试哮喘相关表型,首先使用呼吸道
上皮细胞系(16 HBE)在气液界面培养,然后在基于群体的、年龄合适的模型中
由来自发育中肺分子图谱计划的小儿支气管上皮细胞组成。接下来,
与环境空气中化学品的环境相关比例相匹配的代表性设计混合物将
在标准和基于人群的儿科细胞系中进行评估。这些答复将为目标2提供信息
机制研究,将测试VOC暴露改变EV蛋白表达的假设,
呼吸功能障碍已知炎症和上皮屏障功能由外来体介导,
一类分泌型EV,范围为30至150 nm。在目的2中,将源自暴露于选择性细胞的16 HBE细胞的EV
VOC/混合物将使用高通量蛋白质组学方法进行纯化和测序。蛋白质特征
然后将在不同的儿科供体细胞系中验证该模型中揭示的结果。最后,职能作用
将使用过继转移实验对暴露于VOC的细胞衍生电动汽车进行评估。与目标1和
2、目标3的目标将通过对不同地点的移动的空气监测来表征挥发性有机化合物混合物,
在基线期间和应对环境灾害期间,大休斯顿地区。此外,为了填补
与灾难相关的毒性测试,16 HBE电池将直接暴露于移动的平台上的环境空气中
在现场,使用时间分辨测量来驱动不同空气质量的条件采样。成果
项目2中提出的研究与超级基金计划高度相关。总的来说,新的工具和
研究结果将提高对VOC引起的儿童肺损伤机制的基本理解
并能够改进风险评估,以快速确定威胁儿童健康的呼吸道危害。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Natalie M Johnson其他文献
Natalie M Johnson的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Natalie M Johnson', 18)}}的其他基金
Mechanisms of particulate matter driven infant respiratory disease
颗粒物驱动婴儿呼吸道疾病的机制
- 批准号:
10307553 - 财政年份:2017
- 资助金额:
$ 21.02万 - 项目类别:
Mechanisms of particulate matter driven infant respiratory disease
颗粒物驱动婴儿呼吸道疾病的机制
- 批准号:
10059245 - 财政年份:2017
- 资助金额:
$ 21.02万 - 项目类别:
相似海外基金
Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
- 批准号:
10682121 - 财政年份:2023
- 资助金额:
$ 21.02万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10576370 - 财政年份:2022
- 资助金额:
$ 21.02万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10387023 - 财政年份:2022
- 资助金额:
$ 21.02万 - 项目类别:
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10248409 - 财政年份:2019
- 资助金额:
$ 21.02万 - 项目类别:
A phase I clinical study of adoptive transfer of regulatory T cells (Tregs) and low-dose interleukin-2 (IL-2) for the treatment of chronic graft-versus-host disease (GVHD): gene-marking to inform rational combination therapy
调节性 T 细胞 (Treg) 和低剂量白细胞介素 2 (IL-2) 过继转移治疗慢性移植物抗宿主病 (GVHD) 的 I 期临床研究:基因标记为合理的联合治疗提供信息
- 批准号:
nhmrc : GNT1163111 - 财政年份:2019
- 资助金额:
$ 21.02万 - 项目类别:
Project Grants
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10462684 - 财政年份:2019
- 资助金额:
$ 21.02万 - 项目类别:
Gene edited lymphoid progenitors for adoptive transfer as a treatment of primary immunodeficiency
基因编辑的淋巴祖细胞用于过继转移作为原发性免疫缺陷的治疗
- 批准号:
398018062 - 财政年份:2018
- 资助金额:
$ 21.02万 - 项目类别:
Research Grants
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9308643 - 财政年份:2017
- 资助金额:
$ 21.02万 - 项目类别:
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9447149 - 财政年份:2017
- 资助金额:
$ 21.02万 - 项目类别:
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes
通过程序化 B 淋巴细胞的过继转移靶向癌症 miRNA
- 批准号:
8893915 - 财政年份:2014
- 资助金额:
$ 21.02万 - 项目类别: